KR20230030642A - 시신경척수염 스펙트럼 장애를 치료하는 방법 - Google Patents

시신경척수염 스펙트럼 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20230030642A
KR20230030642A KR1020237002980A KR20237002980A KR20230030642A KR 20230030642 A KR20230030642 A KR 20230030642A KR 1020237002980 A KR1020237002980 A KR 1020237002980A KR 20237002980 A KR20237002980 A KR 20237002980A KR 20230030642 A KR20230030642 A KR 20230030642A
Authority
KR
South Korea
Prior art keywords
subject
nmosd
sgfap
need
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002980A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 리스
엘리제르 카츠
마이클 스미스
나네트 미테레더
Original Assignee
비엘라 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비엘라 바이오, 인크. filed Critical 비엘라 바이오, 인크.
Publication of KR20230030642A publication Critical patent/KR20230030642A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020237002980A 2020-06-30 2021-06-30 시신경척수염 스펙트럼 장애를 치료하는 방법 Pending KR20230030642A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US63/046,133 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US63/052,093 2020-07-15
US202063071092P 2020-08-27 2020-08-27
US63/071,092 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
KR20230030642A true KR20230030642A (ko) 2023-03-06

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002980A Pending KR20230030642A (ko) 2020-06-30 2021-06-30 시신경척수염 스펙트럼 장애를 치료하는 방법

Country Status (11)

Country Link
US (1) US20230406928A1 (https=)
EP (1) EP4172211A4 (https=)
JP (1) JP2023534916A (https=)
KR (1) KR20230030642A (https=)
CN (1) CN116234571A (https=)
AU (1) AU2021299307A1 (https=)
BR (1) BR112022026747A2 (https=)
CA (1) CA3178954A1 (https=)
IL (1) IL299381A (https=)
MX (1) MX2022016236A (https=)
WO (1) WO2022006283A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Also Published As

Publication number Publication date
CA3178954A1 (en) 2022-01-06
IL299381A (en) 2023-02-01
US20230406928A1 (en) 2023-12-21
BR112022026747A2 (pt) 2023-01-24
WO2022006283A3 (en) 2022-02-03
WO2022006283A2 (en) 2022-01-06
EP4172211A2 (en) 2023-05-03
JP2023534916A (ja) 2023-08-15
MX2022016236A (es) 2023-03-29
EP4172211A4 (en) 2024-07-10
CN116234571A (zh) 2023-06-06
AU2021299307A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
Papeix et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
Gentile et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
US20210277111A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
Akaishi et al. Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica
US20230406928A1 (en) Methods of treating neuromyelitis optica spectrum disorder
Nagane et al. Early aggressive treatment strategy against myasthenia gravis
Gallo et al. Overview of the management of relapsing− remitting multiple sclerosis and practical recommendations
KR20230086674A (ko) 파킨슨 질환의 치료
Kale Management of optic neuritis as a clinically first event of multiple sclerosis
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
EP4426349A2 (en) Methods for treating alzheimer's disease
US20140234307A1 (en) Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
TW202317181A (zh) 治療視神經脊髓炎譜系障礙之方法
HK40087593A (zh) 治疗视神经脊髓炎谱系障碍的方法
Boërio et al. Alteration of motor nerve recovery cycle in multiple sclerosis
TW202313111A (zh) 治療阿茲海默症之方法
US20240076369A1 (en) Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators
Coyle et al. Optimizing outcomes in multiple sclerosis–a consensus initiative
Marrie et al. Interferons in secondary progressive multiple sclerosis
Fraser et al. Optic neuritis: pathophysiology, clinical features, and management
Grzybowski et al. Treatment of optic neuritis
Gilad et al. Effect of time to initiation and dose of methylprednisolone on outcome in multiple sclerosis‐related optic neuritis
Chan Optic neuritis
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病
de Beyl SSEPs and prognosis in postanoxic coma: Only short or also long latency responses?

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240627

Comment text: Request for Examination of Application